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Abstract
The relationship between magnetic resonance imaging (MRI) and clinical variables in
patients suspected to have Creutzfeldt-Jakob Disease (CJD) is uncertain. We aimed to
determine which MRI features of CJD (positive or negative), previously described in vivo,
accurately identify CJD, are most reliably detected, vary with disease duration, and whether
combined clinical and imaging features increase diagnostic accuracy for CJD. Prospective
patients suspected of having CJD were referred to the National CJD Research and Surveil-
lance Unit between 1994–2004; post-mortem, brains were sent for MRI and histopathology.
Two neuroradiologists independently assessed MRI for atrophy, white matter hyperintensi-
ties, and caudate, lentiform and pulvinar signals, blind to histopathological diagnosis and
clinical details. We examined differences in variable frequencies using Fisher’s exact tests,
and associations between variables and CJD in logistic regression models. Amongst 200
cases, 118 (59%) with a histopathological diagnosis of CJD and 82 (41%) with histopatho-
logical diagnoses other than CJD, a logistic regression model including age, disease dura-
tion at death, atrophy, white matter hyperintensities, bright or possibly bright caudate, and
present pulvinar sign correctly classified 81% of cases as CJD versus not CJD. Pulvinar
sign alone was not independently associated with an increased likelihood of histopathologi-
cally-confirmed CJD (of any subtype) or sporadic CJD after adjustment for age at death, dis-
ease duration, atrophy, white matter hyperintensities or caudate signal; despite the large
sample, data sparsity precluded investigation of the association of pulvinar sign with variant
CJD. No imaging feature varied significantly with disease duration. Of the positive CJD
signs, neuroradiologists most frequently agreed on the presence or absence of atrophy
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(agreements in 169/200 cases [84.5%]). Combining patient age, and disease duration, with
absence of atrophy and white matter hyperintensities and presence of increased caudate
signal and pulvinar sign predicts CJD with good accuracy. Autopsy remains essential.
Introduction
Creutzfeldt-Jakob disease (CJD) is a fatal neurological disease characterised by a post-transla-
tional conformational change in the prion protein. It most often occurs sporadically (sCJD),
can be genetic, but importantly sometimes is iatrogenic (iCJD) or acquired by zoonotic infec-
tion (variant CJD [vCJD]) arising from dietary contamination with bovine spongiform
encephalopathy[1]. Clinical diagnosis is based on the presence of key clinical features, the
exclusion of other illnesses and supportive test findings, including magnetic resonance imag-
ing (MRI)[2] and cerebrospinal fluid (CSF) protein analyses.
Various brain MRI features have been described in patients with CJD. Most notably these
include increased signal in the caudate and lentiform nucleus in sCJD and, in vCJD, increased
signal in the posterior third of the thalamus compared to other basal ganglia (named the pulvi-
nar sign)[2]. However, CJD is rare. Annual mortality rates from sCJD range between 0.76 and
1.32 per million per year in the United Kingdom[3]. Variant CJD is even rarer, with only 231
cases reported worldwide between October 1996 and July 2017[4]. Most CJD presents in mid-
dle to late life when other neurodegenerative disorders, which may mimic CJD, are common,
adding to the diagnostic difficulty. As most of the data concerning MRI findings in CJD are
derived from routine clinical practice[2, 5], the relationship between the MRI findings and dis-
ease duration or other clinical features is uncertain. Some variation in reported imaging find-
ings may reflect the point in the disease course at which the patient was imaged, as it is often
difficult to undertake MRI in patients with advanced forms of neurodegenerative diseases.
The UK National CJD Research and Surveillance Unit (NCJDRSU) was established in May
1990. From that time onwards, brains of most patients suspected of having died of CJD in the
UK were referred to the Unit for neuropathological analysis, with relatives giving consent for
research, including MRI, in some cases. We aimed to determine, in patients with suspected
CJD in life, whether there were specific (positive or negative) features, or combinations thereof
on visual assessment that identified CJD from non-CJD, vCJD and sCJD at the point of death,
if duration of disease influenced imaging appearances, and which imaging features were most
reliably detected. We were able to achieve these aims using the unique post-mortem MRI data-
set held by the NCJDRSU.
Materials and methods
Patients
The methodology of the UK CJD surveillance system is described elsewhere (http://www.cjd.
ed.ac.uk/sites/default/files/NCJDRSU%20surveillance%20protocol-april%202017%20rev2.pdf). In
brief, wherever possible, alive suspected cases referred to the NCJDRSU are clinically exam-
ined by the Unit neurologist who also reviews case records, records a detailed history, and
takes relevant blood and CSF specimens. To determine a definite diagnosis in as many cases as
possible, autopsy is encouraged and facilitated by transferring brain material to the NCJDRSU
pathology laboratory. During the study period of 1994–2004, 1623 referrals were made to the
NCJDRSU, for whom 184 whole brains and 178 half brains were available. Relatives gave writ-
ten consent for research for 200 deceased suspected cases, resulting in our study sample of
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112/184 (60.9%) of available whole brains, and 88/178 (49.4%) of available half brains. The eth-
ics approval for the use of human tissues in the MRC Edinburgh Brain Bank for research was
recently updated by the East of Scotland Research Ethics Service (reference: 16/ES/008). Sepa-
rate local institutional approval for projects involving human tissue and related data is not
required, but the relevant local institutions (i.e. the University of Edinburgh and NHS Lothian)
are provided with details of the application and their support is required before the application
is submitted to the relevant local ethics committee.
Imaging
We fixed brain specimens in a 10% formalin solution for at least three weeks, then drained the
formalin and dried the specimens before scanning. Post-mortem MRI signal characteristics
are positively correlated with in-vivo measurements[6], and remain stable over long periods
after fixation[7, 8]. We obtained T2 and proton density (PD) weighted MRI on one of three
research-dedicated scanners, which were replaced over the 10-year study period. These
included a 1.0T Siemens Magnetom from 21/10/1994 to 23/11/1998 (TR, TE, slice thickness:
T2 2200, 90, 5 mm; PD 2200, 20, 5 mm), a 2.0T Elscint (now General Electric) Prestige from
08/12/1998 to 01/10/1999 (TR, TE, slice thickness: T2 fast spin echo (FSE) 4800, 128, 5 mm;
PD FSE 4800, 16, 5 mm), and a 1.5T General Electric Signa Echospeed from 27/01/2000
onwards (TR, TE, slice thickness: T2 FSE 2000, 105, 3 mm; PD FSE 2000, 15, 3 mm). We
implemented the MRI sequences to produce as similar brain signals as possible on each scan-
ner, and each was optimized for visual assessment of T2 or PD images as in clinical practice.
We tested different methods of scanning (in or out of fluid, different fluids, different
sequences, scan duration scanning, and methods to minimise vibration artifact) to design the
final protocol. Diffusion weighted images (DWI) were too degraded by large artefacts from air
trapped within sulci or bubbles forming from air dissolved within fluid to be useful. We double
wrapped brain specimens in plastic bags, and rested them on foam pads within the quadrature
head coil on the inferior surface of the frontal lobe(s) and cerebellum/brain stem.
Image reading
Two consultant neuroradiologists independently reviewed images at two separate time peri-
ods, blind to all clinical and pathological data and each other’s readings. Images were printed
on to film for viewing on lightboxes. For each scanner, the images were printed on settings to
give optimal T2 or PD tissue differentiation based on the standard T2 or PD parameters that
were being used in ongoing in vivo studies and clinical exams that were being performed on
the same scanners in the same time period, i.e. printed images were optimised for clinical
radiological rating.
The neuroradiologists recorded the presence or absence of generalised cerebral atrophy and
white matter hyperintensities (S1 File). They rated signals in the caudate nucleus, lentiform
nucleus and posterior third of the thalamus (pulvinar) as bright, possibly bright or normal com-
pared with expected normal signal in these structures based on experience and in relation to
other brain tissues on the same scan. They rated pulvinar signal as brighter, the same, or less
bright than that of the putamen, with brighter signal defining the ‘pulvinar sign.’ They rated all
signals separately on T2 and PD images. After these ratings, they recorded their overall judge-
ment of the diagnosis as either CJD (subtyped in to variant or sporadic), or not CJD.
Neuropathological and clinical data
Neuropathological examinations were performed after brain specimens were imaged. We clas-
sified cases of CJD according to standardised criteria used across Europe (http://www.cjd.ed.
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ac.uk/sites/default/files/criteria_0.pdf) which detail that neuropathological confirmation is
required for definitive diagnosis. The methods used for neuropathological diagnosis are sum-
marized elsewhere (www.cjd.ed.ac.uk/sites/default/files/neuropath.pdf). All cases underwent
the same histopathological examinations for CJD and non-CJD diagnoses including additional
methods as necessary after initial examination. Thus in non-CJD tissue-based diagnosis was
made using the relevant clinical standard histopathological methods.
We used available data on age at death and disease duration from clinical records held at
the NCJDRSU. We collected these data prospectively from several sources: direct interview of
relatives (and patient, if possible) at the time of referral to the NCJDRSU, medical records, and
death certificates.
Statistical analyses
We designated one reader’s (JMW) diagnoses as the reference point and compared these to
neuropathological diagnoses to determine the cases for which correct diagnoses were reached.
We present descriptive statistics of the cohorts’ clinical, neuropathological and imaging data.
We used a two-tailed Fisher’s exact test to examine for significant differences in the frequen-
cies of nominal imaging variables between two groups. We used an independent t-test to
examine for significant differences in the mean of continuous variables between two groups.
We used logistic regression analyses to identify imaging features which may be associated
with CJD compared to not CJD, vCJD compared to not vCJD, and sCJD compared to not
sCJD. We considered the following variables: brain atrophy, white matter hyperintensities, and
ratings of T2 signals of the caudate and lentiform nuclei, and presence of the pulvinar sign. We
excluded variables with low frequencies, or if there were strong relationships between predic-
tors, as regression assumes independence. There was a strong relationship between caudate sig-
nal on T2 and lentiform signal on T2, and as fewer data were available for lentiform ratings, this
was excluded from all three models. No patients with vCJD were rated as having atrophy or
white matter signal change, therefore we excluded these two variables from our model of vCJD
compared to not vCJD. We assessed the calibration of each model using area under the curve.
To assess agreement between observers, and between observers’ final diagnoses and patho-
logical diagnoses, we report percentage of cases agreed on, rather than Kappa which is depen-
dent on prevalence. We used SPSS Statistics (version 22.0.0.1, New York, United States of
America) for statistical analyses.
Results
We imaged 200 brains between 1994 and 2004, of whom 118 (59%) had neuropathological
diagnoses of CJD, 32 (16%) with vCJD, 75 (38%) with sCJD, seven (4%) with iatrogenic CJD
and four (2%) with familial CJD. The remainder had non-CJD diagnoses (Table 1). Whole
brains were available from 112/200 patients (56%), with half brains available from the remain-
ing patients (Table 2).
Patients with CJD were significantly younger at death than patients without CJD (mean age 54
(standard deviation [SD] 20) vs 62 [SD 22] years, p = 0.004) and had significantly longer disease
duration (mean 10 [SD 9] vs 3 [SD 10] months, p<0.0001). Patients with vCJD were significantly
younger than those with sCJD at death (mean age 27 [SD 8] vs 67 [SD 9] years, p<0.0001) and
had significantly longer disease duration (mean 16 [SD 8] vs 7 [SD 6] months, p<0.0001).
Signal changes: CJD vs not CJD
Compared to patients without CJD, patients with CJD were less frequently rated as having
cerebral atrophy (13/118, 11% vs 31/82, 38%, p<0.0001), and white matter hyperintensities
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(16/118, 14% vs 39/82, 48%, p<0.0001). Compared to patients without CJD, patients with CJD
were significantly more frequently rated to have bright or possibly bright caudate and lenti-
form nuclei, and present pulvinar sign on T2 (Fig 1 and Table 2).
Table 1. Included patients.
Diagnosis n Age at death Mean (SD)a Disease duration in months
Mean (SD)a
CJD 118 54 (20) 10 (9)
Sporadic 75 67 (9) 7 (6)
Variant 32 27 (8) 16 (8)
Iatrogenic 7
Familial 4
Non-CJD 82 62 (22) 3 (10)
Neurodegenerative 42 64 (23) 3 (10)
Alzheimer disease 28
Lewy body dementia 12
Alzheimer with Lewy body 2
Other 15 50 (21) 3 (8)
Oedema 5
Encephalopathy 3
Age related changes 2
Chronic subcortical encephalitis 1
John Cunningham virus 1
Motor neurone disease 1
Prader-Willi syndrome 1
Viral encephalitis 1
Vascular 11 66 (25) 1 (5)
Infarct 7
Ischaemia 2
Amyloid angiopathy 1
Arteriovenous malformation 1
Neoplastic 6 72 (6) 1 (2)
Brain metastases 2
Ependymoma 1
Lymphoma 2
Paraneoplastic syndrome 1
Multiple 5 68 (6) 0 (0)
Alzheimer and amyloid angiopathy 1
Alzheimer and Parkinson disease 1
Infarct and small cell carcinoma 1
Infarcts and meningoencephalitis 1
Lewy body and vascular malformation 1
Demyelination 3 58 (7) 19 (19)
Multifocal demyelination 1
Multiple sclerosis 1
Non-specified demyelination 1
SD = standard deviation, CJD = Creutzfeldt-Jakob Disease
a Mean and standard deviation presented for summary groups only
https://doi.org/10.1371/journal.pone.0201434.t001
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A binomial logistic regression model which included patient and imaging variables cor-
rectly classified 81% of cases as CJD or not CJD. The odds of CJD were significantly increased
with increased disease duration (odds ratio (OR) 1.129, 95% confidence interval (CI) 1.071–
1.191, p<0.0001), and bright or possibly bright caudate on T2 (OR 7.854, 95% CI 3.656–
16.874, p<0.0001) and significantly reduced by the presence of atrophy (OR 0.255, 95% CI
0.091–0.713, p = 0.009) (Table 3).
Signal changes: With subtypes of CJD
Compared to patients with sCJD, patients with vCJD were rated significantly more frequently
as having bright or possibly bright pulvinar signals on T2 and PD, and present pulvinar sign
on T2 (Table 2).
Brain atrophy, white matter hyperintensity and pulvinar sign variables were excluded from
a binomial logistic regression model to predict vCJD compared to not vCJD due to data spar-
sity (Table 3, S1 Table). The model included age at death, disease duration and bright or
Table 2. Reference reader signal ratings vs pathology.
CJD (all types)a
n (%)
Not CJDb
n (%)
p value vCJD
n (%)
sCJD
n (%)
p value
n 118 82 32 75
Whole brain 68 (57.6) 44 (53.7) 11 (34.4) 47 (62.7)
Correctly identified by neuroradiologist 89 (75.4) 56 (68.3) 20 (62.5) 28 (37.3)
Brain atrophy 13 (11.0) 31 (37.8) <0.0001 0 (0.0) 11 (14.7) 0.032
White matter hyperintensities 16 (13.6) 39 (47.6) <0.0001 0 (0.0) 15 (20.0) 0.005
Caudate nucleus signal
Bright on T2 60 (50.9) 11 (13.4) <0.0001 16 (50.0) 39 (52.0) 1.000
Bright or possibly bright on T2 85 (72.0) 20 (24.4) <0.0001 24 (75.0) 54 (72.0) 0.816
Bright on PD 107 (90.7) 73 (89.0) 0.812 31 (96.9) 68 (90.7) 0.431
Bright or possibly bright on PD 111 (94.1) 76 (92.7) 0.774 32 (100.0) 70 (93.3) 0.319
Lentiform nucleus signal
Bright on T2 69 (58.5) 14 (17.1) <0.0001 20 (62.5) 43 (57.3) 0.672
Bright or possibly bright on T2 95 (80.5) 28 (34.2) <0.0001 29 (90.6) 58 (77.3) 0.174
Bright on PD 105 (89.0) 69 (84.2) 0.393 27 (84.4) 69 (92.0) 0.299
Bright or possibly bright on PD 112 (94.9) 75 (91.5) 0.388 31 (96.9) 71 (94.7) 1.000
Pulvinar signal
Bright on T2 38 (32.2) 6 (7.3) <0.0001 15 (46.9) 19 (25.3) 0.041
Bright or possibly bright on T2 53 (44.9) 9 (11.0) <0.0001 20 (62.5) 28 (37.3) 0.020
Bright on PD 89 (75.4) 50 (61.0) 0.042 30 (93.8) 54 (72.0) 0.011
Bright or possibly bright on PD 101 (85.6) 57 (69.5) 0.008 31 (96.9) 61 (81.3) 0.036
Pulvinar sign
Present on T2 8 (9.8) 3 (2.5) 0.530 6 (18.8) 2 (2.7) 0.009
Present or pulvinar signal same as putamen on T2 49 (41.5) 17 (20.7) 0.002 20 (62.5) 25 (33.3) 0.010
Present on PD 10 (8.5) 3 (3.7) 0.246 8 (25.0) 2 (2.7) 0.001
Present or pulvinar signal same as putamen on PD 91 (77.1) 49 (59.8) 0.012 29 (90.6) 55 (73.3) 0.070
CJD = Creutzfeldt-Jakob Disease, vCJD = new variant Creutzfeldt-Jakob Disease, sCJD = sporadic Creutzfeldt-Jakob Disease, PD = proton density
Tests: Fisher’s exact 2 sided
a There were four cases of familial and seven cases of iatrogenic CJD included in the cohort
b Six non-CJD cases do not have age at death data
https://doi.org/10.1371/journal.pone.0201434.t002
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possibly bright caudate on T2, and correctly classified 90% of cases as vCJD or not vCJD.
Increased age at death significantly reduced the odds of vCJD (OR 0.420, 95% CI 0.310–0.570,
p<0.0001), whereas increased disease duration significantly increased the odds of vCJD (OR
1.103, 95% CI 1.049–1.161, p<0.0001) (Table 3).
A final binomial logistic regression model correctly classified 82% of cases as sCJD or not
sCJD. The odds of sCJD increased significantly with increased age (OR 2.662, 95% CI 1.954–
3.625, p<0.0001) and disease duration (OR 1.071, 95% CI 1.024–1.119, p = 0.002), and pres-
ence of bright or possibly bright caudate signal on T2 (OR 7.421, 95% CI 3.292–16.731,
p<0.0001). Presence of atrophy and white matter hyperintensities significantly reduced the
odds of sCJD (OR 0.360, 95% CI 0.130–0.992, p = 0.048; OR 0.326, 95% CI 0.124–0.858,
p = 0.024 respectively) (Table 3).
Presence of the pulvinar sign did not significantly increase the odds of CJD or sCJD inde-
pendently of the other factors included in the models (Table 3).
Fig 1. Examples of patients with vCJD, sCJD and non-CJD diagnoses. Axial T2-weighted images of post-mortem brains from patients with suspected CJD,
imaged using 1.0T Siemens Magnetom, with corresponding immunohistochemistry. 1a) Correctly diagnosed by the reference reader as variant CJD, with all
basal ganglia rated as bright, without atrophy or white matter hyperintensities. 1b) Immunohistochemistry for prion protein in the frontal cortex in variant CJD
shows dense staining (brown) of rounded florid plaques, with additional microplaques and pericellular deposits also demonstrated (12F10 antibody, x 100). 2a)
Correctly diagnosed by the reference reader as sCJD, with only the caudate nuclei rated as bright, without a bright pulvinar, or atrophy or white matter
hyperintensities. 2b) Immunohistochemistry for prion protein in the frontal cortex in sporadic CJD (MM2 subtype) shows dense deposition (brown) around
areas of confluent spongiform change (12F10 antibody, x 100). 3a) Correctly diagnosed by the reference reader as non-CJD without any basal ganglia signal
change, but with atrophy and white matter hyperintensities present. 3b) Immunohistochemistry for Aβ in the frontal cortex in Alzheimer’s disease shows
numerous plaques (brown), including a cored plaque (lower right) (6F/3D antibody, x 100).
https://doi.org/10.1371/journal.pone.0201434.g001
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Signal changes in CJD by duration of disease
The mean duration of disease amongst the 118 patients with CJD was 10 months. There was
no significant difference in the frequency of any imaging variable in patients with disease dura-
tion of 10 months or less, compared to those with disease duration greater than 11 months.
Diagnostic accuracy of signs
No individual sign had over 80% sensitivity and specificity for detecting CJD versus not CJD,
or for differentiating vCJD from sCJD (S2 Table). For predicting either vCJD or sCJD, bright
or possibly bright caudate on PD, and bright or possibly bright pulvinar on PD had sensitivi-
ties of over 80%. Bright pulvinar sign on T2 had 97.3% and 81.3% specificity for vCJD and
sCJD respectively, but less than 40% sensitivity for either (S2 Table).
Observer agreement
Observers most frequently agreed on the presence or absence of brain atrophy (agreements in
169/200 cases (84.5%)). Observers least frequently agreed on the rating of caudate signal on
PD as bright compared to possibly bright or not bright (agreed on 50/200 cases (25.0%)).
Observers agreed on final diagnoses in 102/200 (51.0%) of cases (S3 Table).
Comparing one reader’s (JMW) overall judgement of final diagnosis to the histopatholog-
ical diagnosis resulted in agreement on the presence or absence of CJD in 145/200 (72.5%)
cases (Table 4).
Comparing two readers’ (JMW and RS) overall judgements of final diagnosis resulted in
agreement of presence or absence of CJD in 102/200 (51%) cases (S3 Table).
Misdiagnosed cases
There were no significant differences in the availability of whole brains or mean age at death in
patients who were correctly diagnosed with CJD to those who had a diagnosis of CJD missed
by the reference reader, or in patients in whom CJD was overcalled by the reference reader
compared to those in whom a non-CJD diagnosis was correctly made (Table 4). Patients who
were correctly diagnosed with CJD had a significantly shorter duration of disease compared to
Table 3. Logistic regression models.
CJD compared to not CJDa vCJD compared to not vCJDb sCJD compared to not sCJDc
95% confidence
interval
95% confidence
interval
95% confidence
interval
Variable Odds ratio Lower Upper p value Odds ratio Lower Upper p value Odds ratio Lower Upper p value
Age at death 1.102 0.905 1.340 0.334 0.420 0.310 0.570 <0.0001 2.662 1.954 3.625 <0.0001
Disease duration 1.129 1.071 1.191 <0.0001 1.103 1.049 1.161 <0.0001 1.071 1.024 1.119 0.002
Brain atrophyd 0.255 0.091 0.713 0.009 - - - - 0.360 0.130 0.992 0.048
White matter signal changed 0.260 0.103 0.658 0.004 - - - - 0.326 0.124 0.858 0.024
Bright or possibly bright caudate on T2 7.854 3.656 16.874 <0.0001 3.325 0.958 11.536 0.058 7.421 3.292 16.731 <0.0001
Pulvinar signd 3.306 0.674 16.207 0.140 - - - - 0.729 0.115 4.605 0.737
CJD = Creutzfeldt-Jakob disease, vCJD = variant CJD, sCJD = sporadic CJD
a Area under the curve = 0.881 (95% confidence interval 0.831–0.931), p-value <0.0001.
b Area under the curve = 0.950 (95% confidence interval 0.921–0.978), p-value <0.0001.
c Area under the curve = 0.860 (95% confidence interval 0.809–0.911), p-value <0.0001.
d These variables were excluded from the model of vCJD compared to not vCJD due to lack of data (see also S1 Table)
https://doi.org/10.1371/journal.pone.0201434.t003
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those in whom a diagnosis of CJD was missed (9 [SD 7] months vs 13 [SD 1]) months,
p = 0.012). There was a significant difference regarding which scanner was used for imaging in
patients in whom CJD was overcalled by the reference reader compared to those in whom a
non-CJD diagnosis was correctly made (Table 4).
Missed CJD. The reference reader missed 29 cases of CJD (four vCJD, 21 sCJD, and two
cases each of familial and iatrogenic CJD) (Table 4). Compared to patients in whom a diagno-
sis of CJD was correctly made, missed cases were significantly more frequently rated as having
brain atrophy, and significantly less frequently rated as having bright caudate nuclei on T2 and
PD, bright lentiform nuclei on T2 and PD, and bright pulvinar on T2 and PD (Table 4). There
was no difference in the proportion rated as having bright pulvinar sign on either T2 or PD
between these two groups (Table 4).
Overcalled CJD. The reference reader incorrectly diagnosed CJD in 26 patients. Com-
pared to patients in whom a non-CJD diagnosis was correctly made, overcalled cases were
Table 4. Misdiagnoses.
Cases of CJD Cases of non-CJD
Correctly identified
CJD
(n = 89)
n (%)
Missed CJD
(n = 29)
n (%)
p value Correctly identified not CJD (n = 56)
n (%)
Overcalled CJD
(n = 26)
n (%)
p value
Whole brains 54 (60.7) 14 (48.3) 0.282 31 (55.6) 13 (50.0) 0.812
Scanner 1 (1.0 tesla) 49 (55.1) 18 (62.1) 0.258 36 (64.3) 11 (42.3) 0.032
Scanner 2 (2.0 tesla) 12 (13.5) 6 (20.7) 8 (14.3) 2 (7.7)
Scanner 3 (1.5 tesla) 28 (31.5) 5 (17.2) 12 (21.4) 13 (50.0)
Mean age at death in years (SD) 52 (20) 57 (21) 0.246 65 (20) 55 (25) 0.053
Mean disease duration in months (SD) 9 (7) 13 (12) 0.012 3 (11) 3 (7) 0.699
Brain atrophy 6 (6.7) 7 (24.1) 0.016 21 (37.5) 10 (38.5) 1.000
White matter hyperintensities 9 (10.1) 7 (24.1) 0.067 31 (55.4) 8 (30.8) 0.057
Caudate nucleus signal
Bright on T2 57 (64.1) 3 (10.4) <0.0001 0 (0.0) 11 (42.3) <0.0001
Bright or possibly bright on T2 76 (85.4) 9 (31.0) <0.0001 5 (8.9) 15 (57.7) <0.0001
Bright on PD 87 (97.8) 20 (69.0) <0.0001 47 (83.9) 26 (100.0) 0.051
Bright or possibly bright on PD 88 (98.9) 23 (79.3) 0.001 50 (89.3) 26 (100.0) 0.170
Lentiform nucleus signal
Bright on T2 65 (73.0) 4 (13.8) <0.0001 1 (1.8) 13 (50.0) <0.0001
Bright or possibly bright on T2 85 (95.5) 10 (34.5) <0.0001 10 (17.9) 18 (69.2) <0.0001
Bright on PD 83 (93.3) 22 (75.9) 0.016 45 (80.4) 24 (92.3) 0.209
Bright or possibly bright on PD 88 (98.9) 24 (82.8) 0.003 50 (89.3) 25 (96.2) 0.422
Pulvinar signal
Bright on T2 37 (41.6) 1 (3.5) <0.0001 1 (1.8) 5 (19.2) 0.011
Bright or possibly bright on T2 49 (55.1) 4 (13.8) <0.0001 1 (1.8) 8 (30.8) <0.0001
Bright on PD 75 (84.3) 14 (48.3) <0.0001 27 (48.2) 23 (88.5) 0.001
Bright or possibly bright on PD 79 (88.8) 22 (75.9) 0.125 34 (60.7) 23 (88.5) 0.011
Pulvinar sign
Present on T2 6 (6.7) 2 (7.0) 1.000 2 (3.6) 1 (3.9) 1.000
Present or same signal as putamen on T2 42 (47.2) 7 (24.1) 0.032 9 (16.1) 8 (30.8) 0.150
Present on PD 8 (9.0) 2 (6.9) 1.000 2 (3.6) 1 (3.9) 1.000
Present or same signal as putamen on PD 72 (80.9) 19 (65.5) 0.125 27 (48.2) 22 (84.6) 0.002
CJD = Creutzfeldt-Jakob disease, SD = standard deviation, PD = proton density
https://doi.org/10.1371/journal.pone.0201434.t004
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significantly more frequently rated as having bright caudate and lentiform nuclei on T2, bright
pulvinar nuclei on T2 and PD, and bright pulvinar sign on PD (Table 4).
Discussion
We found that brain atrophy and white matter hyperintensities are less frequently present in
patients with CJD, and the presence of bright caudate increases the likelihood of a final diagnosis
of CJD, in this large dataset. Models including patient variables and imaging signs predicted most
CJD versus no CJD, sCJD versus not sCJD, and vCJD versus not vCJD very accurately. Interob-
server agreement regarding MRI signal changes varied, and final diagnoses based on radiologists’
overall judgments of the imaging agreed with pathological diagnoses in 145/200 (72.5%) cases. If
this experiment were repeated by radiologists who were informed of our imaging feature results
and provided with information on disease duration and age (as would be available in clinical prac-
tice), that diagnostic accuracy would likely improve further. Missed cases of CJD were less likely
to have bright basal ganglia, indicating that even at death (i.e. end-stage disease), signs thought
characteristic of CJD and useful in pre-mortem investigations are not 100% sensitive or specific
for CJD post-mortem, and, as our logistic regression models suggest, combinations of patient var-
iables and presence or absence of imaging variables identify most CJD cases, suggesting that, in
contrast to some studies, positive individual imaging signs should not be used alone[5, 9, 10], and
useful negative signs also should be sought to differentiate CJD from non-CJD. Whilst autopsy
rates remain extremely low, neuropathology remains essential for a definitive diagnosis of CJD.
To our knowledge, this study represents one of the largest post-mortem MRI dataset with
pathological correlation in any disease, the largest post-mortem imaging study of patients with
suspected CJD, and is comparable in size to the largest pre-mortem imaging studies of patients
with suspected CJD[9–11]. Three large national surveillance programmes have published data
on cohorts of patients with suspected CJD[10, 12, 13] but none routinely performed or have
published data on post-mortem imaging.
This study also benefits from consistent data collection on a rare disease due to the nation-
wide referral system to the NCJDRSU. The study therefore comprises the largest collection of
neuropathological and neuroimaged brains from unselected patients with suspected CJD,
referred by doctors working across an entire country of approximately 60 million people. The
cohort is entirely representative of, and therefore data are directly relevant to, patients encoun-
tered in routine clinical practice. Compared to in vivo studies of imaging findings performed
in selected groups of CJD patients[5, 9] results from our study are more generalisable to rou-
tine clinical practice where firm diagnosis is yet to be established in patients either late in the
disease process or during virtual autopsy.
Our research MRI scanner hardware was replaced three times during the 10-year study.
Whilst using different scanners undoubtedly creates noise in the dataset, this likely has a lim-
ited effect on the imaging outcome measures, which were derived by visual assessment of stan-
dard structural images rather than quantitative measures, as found by others[10]. As hundreds
of different scanners would be used nationally or internationally to image patients with sus-
pected CJD, our results are generalisable to routine practice. Our T2-weighted imaging pro-
duces similar images to fluid-attenuated inversion recovery (FLAIR) sequences which are
commonly used in pre-mortem imaging of CJD due to the low signal intraventricular air in
our post-mortem specimens. Whilst visual assessment of images may seem simple compared
to digital image analysis techniques, most diagnoses of CJD on imaging in clinical practice are
based on visual assessment, and our imaging outcomes based on visual assessment are imme-
diately applicable to both clinical practice and to research studies performed using different
MRI scanners.
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The radiologists were blinded to clinical and pathological data, reducing the impact of these
on imaging ratings and opinions on final diagnoses. The majority of samples were whole
brains. Availability of only hemi-brains may have reduced accuracy in these 88/200 (44.0%)
patients, particularly if parasagittal nuclei close to tissue-fluid interfaces were affected by arte-
fact, or if lack of a second side affected observers’ certainty regarding signal characteristics.
However, there was no evidence of altered accuracy within our sample, as there was no signifi-
cant association between the availability of whole rather than hemi-brains and the correct
identification of either CJD (p = 0.282) or non-CJD (p = 0.812) (Table 4). The effect of fixation
on signal characteristics is likely to be minimal, particularly T2 signal characteristics of basal
ganglia, which change slowly, even over extended periods[7], and is even less relevant for mea-
sures of relative, rather than absolute, signal changes as used in this study.
Interobserver agreement levels between the two readers, both of whom are experts in the
field, were entirely consistent with other studies of expert neuroradiologists’ agreement on
final diagnoses of CJD and presence/absence of imaging features based on visual inspection of
images[10, 14]. Whilst it appeared that the most recent scanner was associated with increased
overcalling CJD, this is likely a confounder, as overcalling rates did not increase with increased
magnet field strength.
Hospital autopsy rates in the UK have fallen significantly[15] prompting a search for non-
or minimally invasive examination strategies[16], and forensic radiology is a rapidly growing
subspecialty[17]. However, major discrepancies in causes of death identified by consensus
radiology reads of post-mortem MRI compared to autopsy occur in 43% of cases (95% CI 36–
50%)[17], and post-mortem neuroimaging in 57 unselected cases demonstrated sensitivities
ranging from 0 to 100% for the detection of relevant post-mortem findings[18].
This study of the largest cohort of post-mortem imaging in suspected CJD demonstrates
that whilst using combinations of patient and imaging variables can accurately classify non-
CJD and CJD subtypes, no individual or combination of imaging signs is 100% sensitive or
specific, and autopsy remains essential for a definitive diagnosis of human prion disease.
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